Synthesis 2024; 56(14): 2234-2238
DOI: 10.1055/a-2235-5080
paper

Short Synthesis of Dopamine Agonist Rotigotine

Chandra Shekhar
a   Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
b   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
,
Santanu Karmakar
a   Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
b   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
,
Prathama S. Mainkar
a   Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
b   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
,
a   Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
b   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
› Institutsangaben

The authors thank the Council of Scientific and Industrial Research (CSIR), C.S. thanks the University Grants Commission (UGC), and SK thanks CSIR for a research fellowship. S. C. thanks the Science and Engineering Research Board (SERB), Government of India for J C Bose fellowship (SB/S2/JCB-002/2015).


Abstract

A practical and short synthesis of FDA approved drug, Rotigotine, is achieved in two steps from 5-methoxy-2-tetralone, which in turn was synthesised by [4+2] cycloaddition of the in situ generated methoxyaryne from its precursor aryl triflate with benzyloxybutadiene or from 4-methoxyindanone via ring expansion using trimethylsilyldiazomethane.

Supporting Information



Publikationsverlauf

Eingereicht: 10. November 2023

Angenommen nach Revision: 27. Dezember 2023

Accepted Manuscript online:
27. Dezember 2023

Artikel online veröffentlicht:
29. Januar 2024

© 2024. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany